Proteogenomic framework to improve lung cancer screening with biomarkers
Official title: Proteogenomic framework for precision lung cancer screening
Funded at International Agency for Res on Cancer · NIH-11427685 · Data updated 2026-11-12
A biomarker-based approach aims to refine LDCT lung cancer screening so more cancers are caught early while reducing unnecessary procedures.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project start | August 11, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $546,542 |
| NIH project number | 1R01CA316401-01 |
| Project ID | NIH-11427685 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults at risk for lung cancer who are being considered for LDCT screening based on risk criteria.
✕Less likely to help
Individuals with low lung cancer risk or those not undergoing LDCT screening may not benefit.
What this research studies
This project targets people at risk for lung cancer by combining proteogenomics with existing screening methods to better decide who should be screened and how nodules are managed after screening. It uses the INTEGRAL protein panel to enhance risk assessment beyond traditional smoking-based models. The work builds a risk model using multiple protein markers to identify individuals who would benefit most from LDCT and to guide follow-up decisions after screening. By improving accuracy, it could lower false alarms and unnecessary procedures while catching cancers earlier.
Why it matters
Potential benefit: If successful, patients could experience more accurate screening, fewer unnecessary tests, and earlier detection of lung cancer.
How similar studies have gone: Previous biomarker-based models have shown promise in improving screening eligibility and follow-up decisions, with ongoing validation in diverse cohorts.
Where this research is happening
-
International Agency for Res on Cancer
Lyon, France Active
Researchers
- Principal investigator: Johansson, Mattias Alexander — International Agency for Res on Cancer
- Study coordinator: Johansson, Mattias Alexander
Related research
Other NIH-funded projects on the same topics.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Integrated approach to lung screening and quitting for African Americans
A multi-level program aims to boost LDCT lung cancer screening uptake and help African American smokers quit, with support from a comprehensive community-focused plan.
-
Population health approach to boost lung cancer screening at community clinics
A large Utah project aims to help community clinics reach more eligible adults to get low-dose CT lung cancer screening.
-
Group-based tobacco treatment for older adults after lung cancer screening
A study tests a group-based tobacco cessation program for older adults who are getting lung cancer screening to help them quit smoking.
-
Personalized Lung Cancer Screening for Veterans
Aimed at improving who gets screened and how lung cancer is diagnosed among Veterans using personalized tools.
-
Using quitlines to spread lung cancer screening information to people who smoke
A large cancer center project will test two ways of delivering lung cancer screening information to adults who smoke, using quitlines as a trusted channel to reach them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.